The (pre)clinical development process is complex and risky. This is especially true for ATMP. Luckily, expert organisations
are able to deliver strategic support as well as operational capabilities. We have invited at.las members Quality by Design
and Venn Life Sciences to share their view on the ATMP development process and give insight into their experiences. A
double-interview with Dominiek Rossillion (Quality by Design) and Bruno Speder (Venn Life Sciences).
Menu
